The recent transactions involving Gregory S. Moss, Chief Business & Legal Officer at Evommune, Inc. (NASDAQ:EVMN), highlight both divestment and acquisition of the company's common stock. On May 28, 2026, Mr. Moss sold a total value of $324,711 worth of Evommune common shares. It is notable that these sales were executed under the framework of a Rule 10b5-1 trading plan, which he initially adopted on February 26, 2026.
Specifically, Mr. Moss sold 14,223 shares of Evommune common stock. The weighted average price for these sales was calculated at $22.83 per share. These disposals were not uniform in pricing, occurring across multiple transactions with individual prices ranging between $22.50 and $23.42.
Current market data indicates that the stock is trading at $22.17, which represents a decline from the previous closing price of $23.23. Despite this recent dip, the shares have achieved a year-to-date gain of 29.5%. Furthermore, an analysis provided by InvestingPro suggests that the stock may be currently overvalued, noting analyst price targets are set within a range of $50 to $55.
In a contrasting action, Mr. Moss simultaneously increased his holdings through the acquisition of shares via the exercise of employee stock options. He acquired 14,223 common shares at a cost of $1.71 per share, totaling $24,321 in value for this portion of the transaction.
These stock options were subject to a vesting schedule that dictated the release of ownership over time. The plan stipulated that one-fourth (25%) of the shares would vest upon the first anniversary of the grant date. The remaining balance was structured to vest through thirty-six equal monthly installments, contingent upon Mr. Moss maintaining continuous service with the company.
Following these combined transactions, Mr. Moss's direct ownership stake in Evommune common stock stands at 60,835 shares. In addition to his direct holdings, there are 3,175 shares held indirectly through a family trust where he serves as the trustee. While he disclaims beneficial ownership of these securities except for his proportionate pecuniary interest, they represent a material part of his associated holdings.
Mr. Moss also maintains options that grant him the right to acquire an additional 47,845 shares of common stock in the future.
The timing of this insider sale occurs as Evommune approaches its earnings report scheduled for June 10th. The company's market capitalization is reported at $836.71 million. Available information indicates that the firm possesses more cash than debt. Adding to the positive operational outlook, five separate analysts have revised their earnings estimates upward for the upcoming period, although it must be noted that the company is not currently projected to achieve profitability this year.
Risks
- Market valuation concerns persist, with an analysis suggesting the stock may be overvalued given analyst price targets ranging from $50 to $55.
- The company is not expected to achieve profitability in the current year, which represents a sustained financial risk despite cash reserves exceeding debt.
- Future progress remains heavily dependent on successful outcomes and data interpretation from ongoing clinical trials.
More from Insider Trading
Risks
- Market valuation concerns persist, with an analysis suggesting the stock may be overvalued given analyst price targets ranging from $50 to $55.
- The company is not expected to achieve profitability in the current year, which represents a sustained financial risk despite cash reserves exceeding debt.
- Future progress remains heavily dependent on successful outcomes and data interpretation from ongoing clinical trials.